nodes	percent_of_prediction	percent_of_DWPC	metapath
Etravirine—CYP2C19—Teniposide—lymphatic system cancer	0.157	0.219	CbGbCtD
Etravirine—CYP2C9—Teniposide—lymphatic system cancer	0.131	0.182	CbGbCtD
Etravirine—ABCB1—Mitoxantrone—lymphatic system cancer	0.0887	0.124	CbGbCtD
Etravirine—CYP3A4—Cytarabine—lymphatic system cancer	0.0771	0.108	CbGbCtD
Etravirine—CYP3A4—Teniposide—lymphatic system cancer	0.076	0.106	CbGbCtD
Etravirine—ABCB1—Vincristine—lymphatic system cancer	0.061	0.0851	CbGbCtD
Etravirine—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0531	0.0741	CbGbCtD
Etravirine—ABCB1—Methotrexate—lymphatic system cancer	0.037	0.0515	CbGbCtD
Etravirine—CYP3A4—Vincristine—lymphatic system cancer	0.0366	0.051	CbGbCtD
Etravirine—Acute coronary syndrome—Bleomycin—lymphatic system cancer	0.00128	0.00451	CcSEcCtD
Etravirine—Anaemia—Fludarabine—lymphatic system cancer	0.00127	0.00451	CcSEcCtD
Etravirine—Infection—Teniposide—lymphatic system cancer	0.00127	0.0045	CcSEcCtD
Etravirine—Myocardial infarction—Bleomycin—lymphatic system cancer	0.00127	0.00449	CcSEcCtD
Etravirine—Stomatitis—Bleomycin—lymphatic system cancer	0.00126	0.00446	CcSEcCtD
Etravirine—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00125	0.00444	CcSEcCtD
Etravirine—Malaise—Fludarabine—lymphatic system cancer	0.00124	0.0044	CcSEcCtD
Etravirine—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00124	0.00438	CcSEcCtD
Etravirine—Anorexia—Teniposide—lymphatic system cancer	0.00122	0.00432	CcSEcCtD
Etravirine—Convulsion—Fludarabine—lymphatic system cancer	0.00119	0.00423	CcSEcCtD
Etravirine—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00119	0.00421	CcSEcCtD
Etravirine—Discomfort—Fludarabine—lymphatic system cancer	0.00116	0.0041	CcSEcCtD
Etravirine—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.00116	0.00409	CcSEcCtD
Etravirine—Hyperglycaemia—Carmustine—lymphatic system cancer	0.00114	0.00404	CcSEcCtD
Etravirine—Confusional state—Fludarabine—lymphatic system cancer	0.00113	0.00402	CcSEcCtD
Etravirine—Infection—Fludarabine—lymphatic system cancer	0.00112	0.00396	CcSEcCtD
Etravirine—Decreased appetite—Teniposide—lymphatic system cancer	0.00111	0.00394	CcSEcCtD
Etravirine—Renal failure—Carmustine—lymphatic system cancer	0.00111	0.00393	CcSEcCtD
Etravirine—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.00111	0.00392	CcSEcCtD
Etravirine—Vomiting—Mechlorethamine—lymphatic system cancer	0.0011	0.00391	CcSEcCtD
Etravirine—Nervous system disorder—Fludarabine—lymphatic system cancer	0.0011	0.00391	CcSEcCtD
Etravirine—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.0011	0.0039	CcSEcCtD
Etravirine—Stomatitis—Carmustine—lymphatic system cancer	0.0011	0.0039	CcSEcCtD
Etravirine—Rash—Mechlorethamine—lymphatic system cancer	0.0011	0.00388	CcSEcCtD
Etravirine—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00109	0.00387	CcSEcCtD
Etravirine—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00109	0.00385	CcSEcCtD
Etravirine—Anorexia—Fludarabine—lymphatic system cancer	0.00107	0.0038	CcSEcCtD
Etravirine—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.00106	0.00376	CcSEcCtD
Etravirine—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.00106	0.00376	CcSEcCtD
Etravirine—Myocardial infarction—Vincristine—lymphatic system cancer	0.00106	0.00374	CcSEcCtD
Etravirine—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.00106	0.00374	CcSEcCtD
Etravirine—Feeling abnormal—Teniposide—lymphatic system cancer	0.00106	0.00373	CcSEcCtD
Etravirine—Stomatitis—Vincristine—lymphatic system cancer	0.00105	0.00372	CcSEcCtD
Etravirine—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00105	0.00371	CcSEcCtD
Etravirine—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.00104	0.00366	CcSEcCtD
Etravirine—Renal failure—Mitoxantrone—lymphatic system cancer	0.00103	0.00365	CcSEcCtD
Etravirine—Nausea—Mechlorethamine—lymphatic system cancer	0.00103	0.00365	CcSEcCtD
Etravirine—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.00103	0.00364	CcSEcCtD
Etravirine—Stomatitis—Mitoxantrone—lymphatic system cancer	0.00102	0.00362	CcSEcCtD
Etravirine—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.00102	0.00361	CcSEcCtD
Etravirine—Abdominal pain—Teniposide—lymphatic system cancer	0.00101	0.00358	CcSEcCtD
Etravirine—Body temperature increased—Teniposide—lymphatic system cancer	0.00101	0.00358	CcSEcCtD
Etravirine—Paraesthesia—Fludarabine—lymphatic system cancer	0.00101	0.00358	CcSEcCtD
Etravirine—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00101	0.00357	CcSEcCtD
Etravirine—Connective tissue disorder—Carmustine—lymphatic system cancer	0.000996	0.00353	CcSEcCtD
Etravirine—Decreased appetite—Fludarabine—lymphatic system cancer	0.000978	0.00346	CcSEcCtD
Etravirine—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000972	0.00344	CcSEcCtD
Etravirine—Fatigue—Fludarabine—lymphatic system cancer	0.00097	0.00343	CcSEcCtD
Etravirine—Inflammation—Methotrexate—lymphatic system cancer	0.000964	0.00341	CcSEcCtD
Etravirine—Hypoaesthesia—Vincristine—lymphatic system cancer	0.000963	0.00341	CcSEcCtD
Etravirine—Constipation—Fludarabine—lymphatic system cancer	0.000963	0.00341	CcSEcCtD
Etravirine—Pain—Fludarabine—lymphatic system cancer	0.000963	0.00341	CcSEcCtD
Etravirine—Urinary tract disorder—Vincristine—lymphatic system cancer	0.000956	0.00338	CcSEcCtD
Etravirine—Connective tissue disorder—Vincristine—lymphatic system cancer	0.000951	0.00337	CcSEcCtD
Etravirine—Urethral disorder—Vincristine—lymphatic system cancer	0.000949	0.00336	CcSEcCtD
Etravirine—Eye disorder—Carmustine—lymphatic system cancer	0.000948	0.00335	CcSEcCtD
Etravirine—Hypersensitivity—Teniposide—lymphatic system cancer	0.000944	0.00334	CcSEcCtD
Etravirine—Hepatitis—Mitoxantrone—lymphatic system cancer	0.000943	0.00334	CcSEcCtD
Etravirine—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.000938	0.00332	CcSEcCtD
Etravirine—Anaemia—Bleomycin—lymphatic system cancer	0.000935	0.00331	CcSEcCtD
Etravirine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000928	0.00328	CcSEcCtD
Etravirine—Asthenia—Teniposide—lymphatic system cancer	0.000919	0.00325	CcSEcCtD
Etravirine—Malaise—Bleomycin—lymphatic system cancer	0.000912	0.00323	CcSEcCtD
Etravirine—Cardiac disorder—Vincristine—lymphatic system cancer	0.000898	0.00318	CcSEcCtD
Etravirine—Body temperature increased—Fludarabine—lymphatic system cancer	0.00089	0.00315	CcSEcCtD
Etravirine—Mental disorder—Carmustine—lymphatic system cancer	0.000888	0.00314	CcSEcCtD
Etravirine—Malnutrition—Carmustine—lymphatic system cancer	0.000883	0.00312	CcSEcCtD
Etravirine—Angiopathy—Vincristine—lymphatic system cancer	0.000878	0.00311	CcSEcCtD
Etravirine—Diarrhoea—Teniposide—lymphatic system cancer	0.000876	0.0031	CcSEcCtD
Etravirine—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000872	0.00309	CcSEcCtD
Etravirine—Discomfort—Bleomycin—lymphatic system cancer	0.000851	0.00301	CcSEcCtD
Etravirine—Mental disorder—Vincristine—lymphatic system cancer	0.000848	0.003	CcSEcCtD
Etravirine—Gynaecomastia—Methotrexate—lymphatic system cancer	0.000837	0.00296	CcSEcCtD
Etravirine—Confusional state—Bleomycin—lymphatic system cancer	0.000832	0.00294	CcSEcCtD
Etravirine—Vision blurred—Carmustine—lymphatic system cancer	0.000832	0.00294	CcSEcCtD
Etravirine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000829	0.00293	CcSEcCtD
Etravirine—Tremor—Carmustine—lymphatic system cancer	0.000827	0.00293	CcSEcCtD
Etravirine—Infection—Bleomycin—lymphatic system cancer	0.00082	0.0029	CcSEcCtD
Etravirine—Anaemia—Carmustine—lymphatic system cancer	0.000816	0.00289	CcSEcCtD
Etravirine—Vomiting—Teniposide—lymphatic system cancer	0.000814	0.00288	CcSEcCtD
Etravirine—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000808	0.00286	CcSEcCtD
Etravirine—Asthenia—Fludarabine—lymphatic system cancer	0.000808	0.00286	CcSEcCtD
Etravirine—Rash—Teniposide—lymphatic system cancer	0.000807	0.00286	CcSEcCtD
Etravirine—Dermatitis—Teniposide—lymphatic system cancer	0.000807	0.00285	CcSEcCtD
Etravirine—Headache—Teniposide—lymphatic system cancer	0.000802	0.00284	CcSEcCtD
Etravirine—Anorexia—Bleomycin—lymphatic system cancer	0.000787	0.00278	CcSEcCtD
Etravirine—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000781	0.00276	CcSEcCtD
Etravirine—Anaemia—Vincristine—lymphatic system cancer	0.000779	0.00276	CcSEcCtD
Etravirine—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000773	0.00274	CcSEcCtD
Etravirine—Diarrhoea—Fludarabine—lymphatic system cancer	0.00077	0.00272	CcSEcCtD
Etravirine—Convulsion—Carmustine—lymphatic system cancer	0.000765	0.00271	CcSEcCtD
Etravirine—Hypertension—Carmustine—lymphatic system cancer	0.000762	0.0027	CcSEcCtD
Etravirine—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000761	0.00269	CcSEcCtD
Etravirine—Nausea—Teniposide—lymphatic system cancer	0.000761	0.00269	CcSEcCtD
Etravirine—Anaemia—Mitoxantrone—lymphatic system cancer	0.000758	0.00268	CcSEcCtD
Etravirine—Vertigo—Vincristine—lymphatic system cancer	0.000757	0.00268	CcSEcCtD
Etravirine—Hepatic failure—Methotrexate—lymphatic system cancer	0.000755	0.00267	CcSEcCtD
Etravirine—Anxiety—Carmustine—lymphatic system cancer	0.000749	0.00265	CcSEcCtD
Etravirine—Paraesthesia—Bleomycin—lymphatic system cancer	0.000741	0.00262	CcSEcCtD
Etravirine—Malaise—Mitoxantrone—lymphatic system cancer	0.00074	0.00262	CcSEcCtD
Etravirine—Renal failure acute—Methotrexate—lymphatic system cancer	0.000735	0.0026	CcSEcCtD
Etravirine—Convulsion—Vincristine—lymphatic system cancer	0.00073	0.00258	CcSEcCtD
Etravirine—Hypertension—Vincristine—lymphatic system cancer	0.000727	0.00257	CcSEcCtD
Etravirine—Confusional state—Carmustine—lymphatic system cancer	0.000726	0.00257	CcSEcCtD
Etravirine—Decreased appetite—Bleomycin—lymphatic system cancer	0.000717	0.00254	CcSEcCtD
Etravirine—Infection—Carmustine—lymphatic system cancer	0.000716	0.00253	CcSEcCtD
Etravirine—Vomiting—Fludarabine—lymphatic system cancer	0.000716	0.00253	CcSEcCtD
Etravirine—Convulsion—Mitoxantrone—lymphatic system cancer	0.000711	0.00252	CcSEcCtD
Etravirine—Rash—Fludarabine—lymphatic system cancer	0.00071	0.00251	CcSEcCtD
Etravirine—Dermatitis—Fludarabine—lymphatic system cancer	0.000709	0.00251	CcSEcCtD
Etravirine—Hypertension—Mitoxantrone—lymphatic system cancer	0.000708	0.00251	CcSEcCtD
Etravirine—Pain—Bleomycin—lymphatic system cancer	0.000706	0.0025	CcSEcCtD
Etravirine—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000705	0.0025	CcSEcCtD
Etravirine—Headache—Fludarabine—lymphatic system cancer	0.000705	0.00249	CcSEcCtD
Etravirine—Anxiety—Mitoxantrone—lymphatic system cancer	0.000696	0.00246	CcSEcCtD
Etravirine—Discomfort—Mitoxantrone—lymphatic system cancer	0.00069	0.00244	CcSEcCtD
Etravirine—Anorexia—Carmustine—lymphatic system cancer	0.000687	0.00243	CcSEcCtD
Etravirine—Infection—Vincristine—lymphatic system cancer	0.000683	0.00242	CcSEcCtD
Etravirine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00068	0.00241	CcSEcCtD
Etravirine—Confusional state—Mitoxantrone—lymphatic system cancer	0.000675	0.00239	CcSEcCtD
Etravirine—Nervous system disorder—Vincristine—lymphatic system cancer	0.000674	0.00239	CcSEcCtD
Etravirine—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000673	0.00238	CcSEcCtD
Etravirine—Nausea—Fludarabine—lymphatic system cancer	0.000669	0.00237	CcSEcCtD
Etravirine—Infection—Mitoxantrone—lymphatic system cancer	0.000665	0.00235	CcSEcCtD
Etravirine—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000665	0.00235	CcSEcCtD
Etravirine—Shock—Mitoxantrone—lymphatic system cancer	0.000659	0.00233	CcSEcCtD
Etravirine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000656	0.00232	CcSEcCtD
Etravirine—Anorexia—Vincristine—lymphatic system cancer	0.000655	0.00232	CcSEcCtD
Etravirine—Body temperature increased—Bleomycin—lymphatic system cancer	0.000652	0.00231	CcSEcCtD
Etravirine—Insomnia—Carmustine—lymphatic system cancer	0.000652	0.00231	CcSEcCtD
Etravirine—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00065	0.0023	CcSEcCtD
Etravirine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000647	0.00229	CcSEcCtD
Etravirine—Paraesthesia—Carmustine—lymphatic system cancer	0.000647	0.00229	CcSEcCtD
Etravirine—Somnolence—Carmustine—lymphatic system cancer	0.00064	0.00227	CcSEcCtD
Etravirine—Anorexia—Mitoxantrone—lymphatic system cancer	0.000638	0.00226	CcSEcCtD
Etravirine—Decreased appetite—Carmustine—lymphatic system cancer	0.000626	0.00222	CcSEcCtD
Etravirine—Insomnia—Vincristine—lymphatic system cancer	0.000622	0.0022	CcSEcCtD
Etravirine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000622	0.0022	CcSEcCtD
Etravirine—Paraesthesia—Vincristine—lymphatic system cancer	0.000617	0.00218	CcSEcCtD
Etravirine—Pain—Carmustine—lymphatic system cancer	0.000616	0.00218	CcSEcCtD
Etravirine—Constipation—Carmustine—lymphatic system cancer	0.000616	0.00218	CcSEcCtD
Etravirine—Breast disorder—Methotrexate—lymphatic system cancer	0.000613	0.00217	CcSEcCtD
Etravirine—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000611	0.00216	CcSEcCtD
Etravirine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000608	0.00215	CcSEcCtD
Etravirine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000601	0.00213	CcSEcCtD
Etravirine—Decreased appetite—Vincristine—lymphatic system cancer	0.000598	0.00212	CcSEcCtD
Etravirine—Somnolence—Mitoxantrone—lymphatic system cancer	0.000595	0.00211	CcSEcCtD
Etravirine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000594	0.0021	CcSEcCtD
Etravirine—Feeling abnormal—Carmustine—lymphatic system cancer	0.000594	0.0021	CcSEcCtD
Etravirine—Fatigue—Vincristine—lymphatic system cancer	0.000593	0.0021	CcSEcCtD
Etravirine—Asthenia—Bleomycin—lymphatic system cancer	0.000592	0.0021	CcSEcCtD
Etravirine—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000589	0.00208	CcSEcCtD
Etravirine—Pain—Vincristine—lymphatic system cancer	0.000588	0.00208	CcSEcCtD
Etravirine—Constipation—Vincristine—lymphatic system cancer	0.000588	0.00208	CcSEcCtD
Etravirine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000582	0.00206	CcSEcCtD
Etravirine—Eosinophilia—Methotrexate—lymphatic system cancer	0.000581	0.00206	CcSEcCtD
Etravirine—Fatigue—Mitoxantrone—lymphatic system cancer	0.000577	0.00204	CcSEcCtD
Etravirine—Pancreatitis—Methotrexate—lymphatic system cancer	0.000575	0.00204	CcSEcCtD
Etravirine—Pain—Mitoxantrone—lymphatic system cancer	0.000573	0.00203	CcSEcCtD
Etravirine—Constipation—Mitoxantrone—lymphatic system cancer	0.000573	0.00203	CcSEcCtD
Etravirine—Body temperature increased—Carmustine—lymphatic system cancer	0.000569	0.00201	CcSEcCtD
Etravirine—Abdominal pain—Carmustine—lymphatic system cancer	0.000569	0.00201	CcSEcCtD
Etravirine—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000562	0.00199	CcSEcCtD
Etravirine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000552	0.00195	CcSEcCtD
Etravirine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000548	0.00194	CcSEcCtD
Etravirine—Body temperature increased—Vincristine—lymphatic system cancer	0.000544	0.00192	CcSEcCtD
Etravirine—Abdominal pain—Vincristine—lymphatic system cancer	0.000544	0.00192	CcSEcCtD
Etravirine—Hypersensitivity—Carmustine—lymphatic system cancer	0.000531	0.00188	CcSEcCtD
Etravirine—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000529	0.00187	CcSEcCtD
Etravirine—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000529	0.00187	CcSEcCtD
Etravirine—Vomiting—Bleomycin—lymphatic system cancer	0.000525	0.00186	CcSEcCtD
Etravirine—Rash—Bleomycin—lymphatic system cancer	0.00052	0.00184	CcSEcCtD
Etravirine—Dermatitis—Bleomycin—lymphatic system cancer	0.00052	0.00184	CcSEcCtD
Etravirine—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000519	0.00184	CcSEcCtD
Etravirine—Asthenia—Carmustine—lymphatic system cancer	0.000517	0.00183	CcSEcCtD
Etravirine—Renal failure—Methotrexate—lymphatic system cancer	0.000514	0.00182	CcSEcCtD
Etravirine—Stomatitis—Methotrexate—lymphatic system cancer	0.00051	0.0018	CcSEcCtD
Etravirine—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000509	0.0018	CcSEcCtD
Etravirine—Hypersensitivity—Vincristine—lymphatic system cancer	0.000507	0.00179	CcSEcCtD
Etravirine—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000495	0.00175	CcSEcCtD
Etravirine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000493	0.00175	CcSEcCtD
Etravirine—Asthenia—Vincristine—lymphatic system cancer	0.000493	0.00175	CcSEcCtD
Etravirine—Diarrhoea—Carmustine—lymphatic system cancer	0.000493	0.00174	CcSEcCtD
Etravirine—Nausea—Bleomycin—lymphatic system cancer	0.00049	0.00173	CcSEcCtD
Etravirine—Asthenia—Mitoxantrone—lymphatic system cancer	0.00048	0.0017	CcSEcCtD
Etravirine—Dizziness—Carmustine—lymphatic system cancer	0.000476	0.00169	CcSEcCtD
Etravirine—Diarrhoea—Vincristine—lymphatic system cancer	0.000471	0.00166	CcSEcCtD
Etravirine—Hepatitis—Methotrexate—lymphatic system cancer	0.00047	0.00166	CcSEcCtD
Etravirine—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000464	0.00164	CcSEcCtD
Etravirine—Urethral disorder—Methotrexate—lymphatic system cancer	0.00046	0.00163	CcSEcCtD
Etravirine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000458	0.00162	CcSEcCtD
Etravirine—Vomiting—Carmustine—lymphatic system cancer	0.000458	0.00162	CcSEcCtD
Etravirine—Dizziness—Vincristine—lymphatic system cancer	0.000455	0.00161	CcSEcCtD
Etravirine—Rash—Carmustine—lymphatic system cancer	0.000454	0.00161	CcSEcCtD
Etravirine—Dermatitis—Carmustine—lymphatic system cancer	0.000454	0.00161	CcSEcCtD
Etravirine—Headache—Carmustine—lymphatic system cancer	0.000451	0.0016	CcSEcCtD
Etravirine—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000444	0.00157	CcSEcCtD
Etravirine—Eye disorder—Methotrexate—lymphatic system cancer	0.000439	0.00155	CcSEcCtD
Etravirine—Vomiting—Vincristine—lymphatic system cancer	0.000437	0.00155	CcSEcCtD
Etravirine—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000436	0.00154	CcSEcCtD
Etravirine—Rash—Vincristine—lymphatic system cancer	0.000434	0.00153	CcSEcCtD
Etravirine—Dermatitis—Vincristine—lymphatic system cancer	0.000433	0.00153	CcSEcCtD
Etravirine—Headache—Vincristine—lymphatic system cancer	0.000431	0.00152	CcSEcCtD
Etravirine—Nausea—Carmustine—lymphatic system cancer	0.000428	0.00151	CcSEcCtD
Etravirine—Angiopathy—Methotrexate—lymphatic system cancer	0.000426	0.00151	CcSEcCtD
Etravirine—Vomiting—Mitoxantrone—lymphatic system cancer	0.000426	0.00151	CcSEcCtD
Etravirine—Immune system disorder—Methotrexate—lymphatic system cancer	0.000424	0.0015	CcSEcCtD
Etravirine—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000423	0.0015	CcSEcCtD
Etravirine—Rash—Mitoxantrone—lymphatic system cancer	0.000422	0.00149	CcSEcCtD
Etravirine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000422	0.00149	CcSEcCtD
Etravirine—Headache—Mitoxantrone—lymphatic system cancer	0.00042	0.00148	CcSEcCtD
Etravirine—Mental disorder—Methotrexate—lymphatic system cancer	0.000411	0.00146	CcSEcCtD
Etravirine—Malnutrition—Methotrexate—lymphatic system cancer	0.000409	0.00145	CcSEcCtD
Etravirine—Nausea—Vincristine—lymphatic system cancer	0.000408	0.00145	CcSEcCtD
Etravirine—Nausea—Mitoxantrone—lymphatic system cancer	0.000398	0.00141	CcSEcCtD
Etravirine—Vision blurred—Methotrexate—lymphatic system cancer	0.000385	0.00136	CcSEcCtD
Etravirine—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000379	0.00134	CcSEcCtD
Etravirine—Anaemia—Methotrexate—lymphatic system cancer	0.000378	0.00134	CcSEcCtD
Etravirine—Malaise—Methotrexate—lymphatic system cancer	0.000369	0.0013	CcSEcCtD
Etravirine—Vertigo—Methotrexate—lymphatic system cancer	0.000367	0.0013	CcSEcCtD
Etravirine—Convulsion—Methotrexate—lymphatic system cancer	0.000354	0.00125	CcSEcCtD
Etravirine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000346	0.00122	CcSEcCtD
Etravirine—Discomfort—Methotrexate—lymphatic system cancer	0.000344	0.00122	CcSEcCtD
Etravirine—Confusional state—Methotrexate—lymphatic system cancer	0.000336	0.00119	CcSEcCtD
Etravirine—Infection—Methotrexate—lymphatic system cancer	0.000331	0.00117	CcSEcCtD
Etravirine—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000327	0.00116	CcSEcCtD
Etravirine—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000327	0.00116	CcSEcCtD
Etravirine—Skin disorder—Methotrexate—lymphatic system cancer	0.000324	0.00115	CcSEcCtD
Etravirine—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000323	0.00114	CcSEcCtD
Etravirine—Anorexia—Methotrexate—lymphatic system cancer	0.000318	0.00113	CcSEcCtD
Etravirine—Insomnia—Methotrexate—lymphatic system cancer	0.000302	0.00107	CcSEcCtD
Etravirine—Paraesthesia—Methotrexate—lymphatic system cancer	0.0003	0.00106	CcSEcCtD
Etravirine—Somnolence—Methotrexate—lymphatic system cancer	0.000297	0.00105	CcSEcCtD
Etravirine—Decreased appetite—Methotrexate—lymphatic system cancer	0.00029	0.00103	CcSEcCtD
Etravirine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000288	0.00102	CcSEcCtD
Etravirine—Fatigue—Methotrexate—lymphatic system cancer	0.000288	0.00102	CcSEcCtD
Etravirine—Pain—Methotrexate—lymphatic system cancer	0.000285	0.00101	CcSEcCtD
Etravirine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000275	0.000973	CcSEcCtD
Etravirine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000273	0.000965	CcSEcCtD
Etravirine—Body temperature increased—Methotrexate—lymphatic system cancer	0.000264	0.000933	CcSEcCtD
Etravirine—Abdominal pain—Methotrexate—lymphatic system cancer	0.000264	0.000933	CcSEcCtD
Etravirine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000246	0.00087	CcSEcCtD
Etravirine—Asthenia—Methotrexate—lymphatic system cancer	0.000239	0.000847	CcSEcCtD
Etravirine—Diarrhoea—Methotrexate—lymphatic system cancer	0.000228	0.000808	CcSEcCtD
Etravirine—Dizziness—Methotrexate—lymphatic system cancer	0.000221	0.000781	CcSEcCtD
Etravirine—Vomiting—Methotrexate—lymphatic system cancer	0.000212	0.000751	CcSEcCtD
Etravirine—Rash—Methotrexate—lymphatic system cancer	0.00021	0.000744	CcSEcCtD
Etravirine—Dermatitis—Methotrexate—lymphatic system cancer	0.00021	0.000744	CcSEcCtD
Etravirine—Headache—Methotrexate—lymphatic system cancer	0.000209	0.00074	CcSEcCtD
Etravirine—Nausea—Methotrexate—lymphatic system cancer	0.000198	0.000701	CcSEcCtD
